🔗 Share this article

Given that the United States proceeds with historic changes to its immunization recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by questioning Covid vaccines in the pandemic and has concentrated on potential fatalities after COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Schedule

Agency leaders planned to reveal major revisions to the childhood vaccine schedule recently, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the international standard with no evidence for improved outcomes. This reveal has been delayed until the new year.

Instead of the top vaccines chief, Høeg is set to address the audience at the event. She was just designated temporary leader of the FDA’s CDER, the fifth person to lead the office this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for halting specific childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccines – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in drug development, oversight or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She has no expertise in industry regulation.”

Past heads of CBER would “understand legal statutes and the research of drug development”, noted Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who headed CBER have had.”

CDER has an immense portfolio at the FDA, Woodcock stated.

“Many people just pays attention on the new drug program, but the off-patent medication office clears a multitude of generic medications. There’s a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial management aspect to the position, which supervises over 5,000 staff members. “It is a enormous administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Initiatives

When asked about concerns about Høeg’s credentials and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a representative responded that the “concerns are based on inaccurate presumptions”.

“Her experience aligns with the functions of her job,” the official said, citing the months Dr. Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a disputed one-day medication authorization process that apparently troubled her preceding directors. “How are these therapies being picked for this fast-track system? Who is making the calls?” Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, aside from vaccines.”

Established Track Record on Immunizations

Concerning immunizations, Høeg has a more established, if problematic, history, some experts said. She released a research paper using unconfirmed volunteer-provided data to estimate the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new administration included changing rules for novel immunizations and halting “non-essential” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccines.

“She is an thorough ideologue who starts off with her conclusions and tailors the evidence to accommodate the data in a very deceptive, fraudulent way,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|